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bilateral hands and foots, serological absence of rheumatoid factor,
and a fast response to steroid therapy (10). In this study, two male
patients were complicated by malignant diseases, hepatoma and
lung cancer, after the diagnosis with RS3PE syndrome. Since two
patients who complicated with malignant diseases (hepatoma and
lung cancer) were excluded from this study because malignant
diseases might affect the clinical course of PMR and RS3PE syn-
drome, 24 patients were included in this study.
After the diagnosis, all patients were treated with initial dosages of
10-20 mg per day oral prednisolone according to 2015 Recommen-
dations for the management of PMR (11). Clinical assessments
included symptoms and the measurement of serum CRP by stan-
dard laboratory methods because elevated levels of CRP are
common in patients with PMR and RS3PE syndrome (12). Visits
were scheduled every 2 to 4 weeks, and at each visit the dosage of
prednisolone was tapered by a tapering schedule of 1 to 2.5 mg
reduction when no specific symptoms were complained and CRP
was normal or nearly normal. Prednisolone free remission was
defined as the absence of clinical symptoms and normal levels of
CRP with discontinuation of any drugs which control the diseases
including corticosteroids. A relapse was defined as an aggravation
or reappearance of clinical symptoms associated with an elevated
CRP. If the disease activity relapsed after dose tapering, the predni-
solone was increased to dosages related to the disease requiring.
This study was conducted in accordance with the Declaration of
Helsinki 1975, as revised in 2008 and approved by the Tokushima
University Hospital Research Ethics Board.
Statistical analysis
Comparison between groups was made using Mann-Whitney U
test for continuous variables and Pearson’s chi -squared test for
categorical variables. Data were mainly presented as median and
(25th -75th quarter), meanstandard deviation (SD), count and
(percentage), or odds ratio (OR) and 95% confidence interval (CI).
The results were regarded as significant when p value was0.05.
All statistical analyses were performed using IBM SPSS statistics
version 24 software (Chicago, IL, USA).
RESULTS
Patient characteristics and clinical findings
Table 1 shows the summary of clinical and laboratory variables.
Twenty four patients were included in this study. Eighteen patients
were diagnosed as PMR and 6 patients of RS3PE syndrome. Patients
consisted of 16 women (67%) and 8 men (33%) with median age of
74.5 y.o. (range 62-88). The level of CRP before the treatment
(initial CRP) was elevated in all cases (median ; 8.7 mg/dl, range ;
2.9 -14.7). All patients were treated with oral prednisolone (median ;
15 mg/day, range ; 10-20). The median duration from onset to
treatment start was 8 weeks (range ; 1-52 weeks). The clinical
responses during 1 year since the treatment start (till 1 year) and
during 2 years since the treatment start (till 2 years) were exam-
ined. The level of CRP was decreased 4 weeks after the treatment
(median ; 0.65 mg/dl, range ; 0.05-6.08). Prednisolone free remis-
sion was seen in a patient (4.2%) and 4 patients (16.7%) till 1 year
and 2 years, respectively. A relapse was shown in 4 patients (16.7%)
and 7 patients (29.2%) till 1 year and 2 years, respectively.
The percentage of women was significantly (p=0.003) more in
PMR (83.3%) than in RS3PE syndrome (16.7%), but no significance
was seen in the other variables such as age, the duration from
onset to treatment start, CRP levels, starting doses of prednisolone,
duration from initial treatment to negative CRP, or the rate of
relapse between PMR and RS3PE syndrome.
The relation of initial CRP levels with disease control
The level of initial CRP was compared between two groups
divided by disease control status of patients who were followed up
for 1 year and 2 years after the treatment. The mean dosage of
prednisolone after 1 year was 4.22.3 (median ; 4) mg/day in
patients without relapse. Therefore, patients were divided into two
groups according to prednisolone dosages after 1 year ; one group
consisted of patients treated with less than 5 mg of prednisolone
(Good control), the other group of those treated with 5 mg or
more of prednisolone (Poor control). Patients who had shown
relapse till 1 year were included in Poor control. No patients who
had shown relapse till 1 year received less than 5 mg of predniso-
lone after 1 year. As shown in Fig. 1A, significantly higher initial
CRP levels were observed in Poor control than in Good control.
Significantly higher initial CRP was also observed in patients with
relapse than in those without relapse till 1 year (Fig. 1B) and till 2
Table1 Clinical features of patients
Variables (n=24) values
PMR/RS3PE syndrome 18 (75%)/6 (25%)
Gender, men/women 8 (33% )/16 (67%)
Age, years 74.5 (71.3 -81.8)
Initial CRP, mg/dl ; normal range0.3 8.7(4.2 -10.8)
Starting dose of prednisolone, mg/day 15.0 (11.3 -15.0)
Duration from onset to treatment start, weeks 8.0 (4.3 -15.5)
CRP after 4 weeks, mg/dl 0.65 (0.11 -0.97)
Duration from initial treatment to negative CRP, weeks 7.5 (3.3 -12.8)
Becoming negative CRP after 4 weeks 8 (33.3%)
Becoming negative CRP after 8 weeks 13 (54.2%)
Prednisolone free remission till 1 year 1 ( 4.2%)
Prednisolone free remission till 2 years 4 (16.7%)
Relapse till 1 year 4 (16.7%)
Relapse till 2 years 7 (29.2%)
PMR ; polymyalgia rheumatica, RS3PE ; remitting seronegative symmetrical synovitis with pitting edema. Twenty five patients were included in this
study. Data were presented as counts and (percentage), or median and (interquartile range).
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years (Fig. 1C). Duration from onset to treatment start was not
significantly different between patients in Good control and Poor
control after 1 year (Fig. 2). Disease difference (PMR or RS3PE
syndrome), age, or gender did not affect disease control status
after 1 year and 2 years (data not shown).
The relation of duration from the treatment start to becomingCRP
negative with disease control
Whether duration from treatment start with prednisolone to
becoming CRP negative correspond to the subsequent disease
control status was examined. The duration was significantly longer
in patients in Poor control after 1 year than in those in Good control
after 1 year (Fig. 3A). The duration was also significantly longer in
patients with relapse till 1 year and till 2 years than in those without
relapse (Figs. 3B and 3C, respectively). These data suggest that to
make CRP negative earlier resulted in good suppression of the
disease activity and in decreasing the dosage of prednisolone.
The relation of CRP positivity after 4 weeks with disease control
We next examined the relation of time course of CRP with
disease control status. Patients were divided into two groups, High
CRP and Low CRP, by the median level of initial CRP (8.7 mg/dl)
followed by comparing CRP positivity after 4 weeks and disease
control status after 1 year (Fig. 4). Before the treatment, 12 patients
(50%) were included in High CRP, and 12 (50%) were in Low CRP.
After 4 weeks, 3 patients (25%) were in Negative CRP group from
initial High CRP, but more patients (n=5, 42%) were in Negative
CRP group from initial Low CRP. On the other hand, 1 year after the
treatment, all of patients with Negative CRP after 4 weeks were
included in Good control in spite of initial CRP levels. These results
indicate that patients could be in Good control after 1 year when
CRP after 4 weeks was negative even if they had initial High CRP.
Next, the relation of initial CRP, CRP positivity after 4 weeks, and
disease control disease status after 1 year was further examined by
chi -squared test. As shown in Table 2, initial CRP levels were not
associated with CRP positivity after 4 weeks (OR ; 2.14, 95%CI ;
0.38-12.2, p=0.386). On the other hand, CRP positivity after 4
weeks was significantly associated with disease control status
after 1 year (OR ; 3.20, 95%CI ; 1.55-6.62, p=0.001). As shown in
Table 3, CRP positivity after 8 weeks was also significantly associ-
ated with disease control status after 1 year (OR ; 24.75, 95%CI ;
2.89-212.23, p=0.001).
The relation between initial CRP level and starting doses of
prednisolone
All patients were treated with oral prednisolone after the diagno-
sis. Initial prescription dosages of prednisolone had been decided
by a judgement of a doctor which depended on patient’s total
disease activity. Six patients were treated with 10 mg/day, 17
patients with 15 mg/day, and a patient with 20 mg/day. Patients
Figure 1. The relation of initial CRP levels with disease control 1 year and 2 years after the treatment. A) Initial CRP levels comparing between
patients with Good control and Poor control after 1 year. Patients were divided into two groups according to prednisolone dosages after 1 year ; one
group consisted of patients treated with less than 5 mg of prednisolone (Good control), the other group of those treated with 5 mg or more of
prednisone(Poorcontrol).Patientswhohadshowedrelapse till 1yearwere included inPoorcontrol.B) InitialCRPlevelscomparingbetweenpatients
with and without relapse after 1 year. C) Initial CRP levels comparing between patients with and without relapse after 2 years.
Figure 2. The relation of duration from onset to treatment start with
disease control status 1 year after the treatment. Patients were divided
into two groups according to prednisolone dosages after 1 year ; one
group consisted of patients treated with less than 5 mg of prednisolone
(Good control), the other group of those treated with 5 mg or more of
prednisone (Poor control). Patients who had showed relapse till 1 year
were included in Poor control.
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were divided into 2 groups by the starting doses of prednisolone, 10
mg per day or over 10 mg per day, and then clinical findings were
compared between 2 groups. Although the level of initial CRP
tended to be higher in10 mg group than in 10 mg group, there
was no significant difference (Fig. 5), indicating that starting dosage
might not be decided only by initial levels of CRP. The starting
dose of prednisolone did not affect CRP positivity after 4 weeks or
the disease control status after 1 year (data not shown).
DISCUSSION
This study demonstrates that CRP is a crucial marker to predict
the disease control after the treatment with corticosteroids. Patients
with high initial CRP showed poor disease control after 1 year and 2
years, and to make CRP negative early resulted in subsequent good
control status. Although there have been some reports which dem-
Figure 3. The relation of duration from treatment start to becoming CRP negative with disease control status. A) Comparison of duration from
treatment start to becoming CRP negative between patients in Good control and Poor control after 1 year, as described in the legend of Figure 1. B)
Comparison of duration from treatment start to becoming CRP negative between patients with relapse and without relapse after 1 year. C)Comparison of
duration from treatment start to becoming CRP negative between patients with relapse and without relapse after 2 years.
Figure 4. The relation between time course of CRP and disease control
status. Patients were divided into two groups by the median level of initial
CRP (8.7 mg/dl). After the treatment, patients were divided into two
groups by the positivity of CRP, positive or negative, after 4 weeks and
were divided into two groups, Good control and Poor control, in 1 year, as
described in the legend of Figure 1.
Table 2 The relation among initial CRP, CRP positivity after 4 weeks, and disease control status after 1 year
Initial CRP n (%) CRP after 4weeks n (%)
Control status
after 1 year n (%) OR 95% CI P value
High (8.7) 12 (50)
Positive 9 (75)
Negative 3 (25) 2.14 0.38 −12.2 P=0.386




Poor control 11 (69)
Good control 5 (31)
3.20 1.55− 6.62 P=0.001
Negative 8 (33)
Poor control 0 (0)
Good control 8 (100)
Patients were divided into two groups by median value of initial CRP (8.7 mg/dl). Four weeks after the treatment, patients were divided into two
groups by the positivity of CRP, positive and negative. Patients were divided into two groups according to prednisolone dosages after 1 year ; one
group consisted of patients treated with less than 5 mg of prednisolone (Good control), the other group of those treated with 5 mg or more of
prednisolone (Poor control). Patients who had showed relapse till 1 year were included in Poor control group. P values were calculated using
Pearson’s chi -square test. OR ; odds ratio, CI ; confidence interval
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onstrate the relation between initial CRP levels and the subsequent
therapeutic responses, discrepancies are present in the reports.
PMR patients with an initial CRP2.5 mg/dl have a greater possi-
bility of relapse (2), and high levels of initial CRP are predominantly
distributed in patients with RS3PE syndrome whose CRP level
after 1 year is0.5 mg/dl (4). On the other hand, there have been
reports which demonstrate that initial levels of CRP do not affect
the clinical response of PMR (13, 14) or RS3PE syndrome (15). The
differences are suggested to be due to therapeutic strategies such
as the difference in starting dosage and dose tapering speed of
corticosteroids.
We found that the positivity of CRP after 4 weeks was a crucial
marker of the disease control after 1 year and 2 years. Patients
were in good disease control after 1 year when CRP after 4 weeks
could become negative even if initial CRP levels were high. This is
the first study which focuses on the early response of CRP to the
therapy, and indicates that the positivity of CRP after 4 weeks is
more crucial predictor of subsequent poor disease control and
relapse in PMR and RS3PE syndrome than initial CRP levels.
Although CRP positivity after 8 weeks also predicted the disease
control status after 1 year, CRP levels after 4 weeks may be more
useful as an earlier predictor. There was no significant difference in
initial CRP levels among starting dosages of prednisolone. In this
study, most patients (71%) were treated with same initial dosage
(15 mg/day) according to the suggestion by the British Society for
Rheumatology (BSR) which recommended a starting dosage of 15
mg/day of prednisolone for PMR (16). More initial dosages or
longer duration of prednisolone may be needed to patients with
high level of initial CRP. It is important to select an appropriate
starting dosage and tapering speed of prednisolone for each patient.
Less starting dosages of prednisolone and fast tapering speed may
result in subsequent relapse. Conversely, over dosages and slow
tapering speed may induce various adverse events such as infection
and osteoporosis especially in elderly patients. On the other hand,
some previous reports showed that clinical relapse is not statisti-
cally linked to the initial dosages of corticosteroids (2,17,18). A
previous report showed that the factor predicting a good response to
the therapy of PMR is low body weight but not the disease severity
(19). Further studies are needed to determine how an appropriate
starting dosage and duration of prednisolone for each patient with
PMR and RS3PE syndrome should be determined.
In this study, no significant difference was seen between duration
from the onset to treatment start and subsequent disease control
status, indicating that the delay in treatment start may not affect the
subsequent therapeutic response and prognosis. The result was
not in agreement with a previous report that the duration of symp-
toms before diagnosis is longer in PMR patients with relapse
than in those without relapse (20). The reason of the difference is
not clear because there is no difference in clinical features such as
the mean duration of symptoms before diagnosis and starting
prednisolone dosages between the report and this study. On the
other hand, in this study, there was no significant difference be-
tween men and women in the disease control of patients with
PMR or RS3PE syndrome. Origuchi et al. reported that male
gender is predominantly distributed in patients with RS3PE syn-
drome whose response to corticosteroids is poor (4). Other previous
reports showed that there are more female in relapse group of
patients with PMR (2, 21, 22). Mackie et al. (23) showed that female
gender increases the risk of late GCA that needs high dosages of
corticosteroids to prevent severe complications such as blindness
and cerebral infarction (24-26). In this study, none of the patients
complicated GCA during the follow-up. Thus, the rate of complica-
tions such as GCA is possible to contribute to the difference in the
response to corticosteroids observed in gender.
We measured CRP levels as a marker of disease activity of PMR
and RS3PE syndrome in this study. The erythrocyte sedimentation
rate (ESR) has been known to be useful to examine the activity of
these diseases as well as CRP (2, 6). However, we selected CRP in
this study because ESR might be influenced by various factors
Table 3 The relation among initial CRP, CRP positivity after 8 weeks, and disease control status after 1 year
Initial CRP n (%) CRP after 8weeks n (%)
Control status
after 1 year n (%) OR 95% CI P value
High (8.7) 12 (50)
Positive 8 (67)
Negative 4 (33) 6.00 1.02 − 35.37 P=0.041




Poor control 9 (82)
Good control 2 (18)
24.75 2.89 − 212.23 P=0.001
Negative 13 (54)
Poor control 2 (15)
Good control 11 (85)
Patients were divided into two groups by median value of initial CRP (8.7 mg/dl). Eight weeks after the treatment, patients were divided into two
groups by the positivity of CRP, positive and negative. Patients were divided into two groups according to prednisolone dosages after 1 year ; one
group consisted of patients treated with less than 5 mg of prednisolone (Good control), the other group of those treated with 5 mg or more of
prednisolone (Poor control). Patients who had showed relapse till 1 year were included in Poor control group. P values were calculated using
Pearson’s chi -square test. OR ; odds ratio, CI ; confidence interval
Figure 5. The relation of initial CRP levels with starting doses of
prednisolone. Patients were divided into two groups according to starting
doses of prednisolone, 10 mg or over 10 mg per day, and initial CRP levels
were compared between the two groups.
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such as anemia.
In this study, we examined the predictive factors associated with
the therapeutic response in patients together with PMR and RS3PE
syndrome. PMR and RS3PE syndrome are common diseases in the
elderly, and conventionally treated with long-term oral corticoster-
oids (2, 4). PMR and RS3PE syndrome have various common
characteristics ; both are common rheumatic disorders in the
elderly, and show suddenly occurred clinical symptoms, elevation
of acute phase reactants such as CRP, negative rheumatoid factor,
and effective low dosages of corticosteroids. Synovitis of peripheral
joints, which are characterized by RS3PE syndrome, is also pre-
sent in up to 25% of patients with PMR (27-30). The rate of associ-
ated malignancy was reported not to be different between RS3PE
syndrome and PMR (31) though it has been known to be character-
ized by RS3PE syndrome (3, 4). This study also showed that there
were no significant differences between PMR and RS3PE syn-
drome in various clinical features except gender. Taken together, in
this study, clinical factors predicting the disease control were
examined together in patients with PMR and RS3PE syndrome.
Many reports have shown the therapeutic responses after the
treatment with corticosteroid in patients with PMR and RS3PE
syndrome (2, 4, 18) Previous reports showed that 52-56% of patients
have a complete response to corticosteroid therapy (8, 32, 33). An
overall steroid cessation rate in patients with PMR is only 2.5% at 1
year (2), and 24% of patients with PMR is able to stop corticosteroid
treatment after 2 years (18). Origuchi et al. showed that 82.9% of
patients with RS3PE syndrome are still receiving corticosteroids 1
year after the treatment and 58.5% of the patients are still receiving
over 5 mg/day prednisolone (4). This study showed that 4.2% and
16.7% of patients were in prednisolone-free remission after 1 year
and 2 years, respectively, and the mean dosage of prednisolone
without relapse was 4.2 mg/day after 1 year. Thus, results about
therapeutic response in this study were consistent with previous
reports.
CONCLUSION
In this study, we demonstrate that earlier negativity of CRP by
the treatment may be important to aim low disease activity and the
prevention of relapse of PMR and RS3PE syndrome. However, our
study is limited by the fact that it is a retrospective study per-
formed in two hospitals. Future prospective studies are needed to
conform our findings. A clinical study to determine an appropriate
starting dosage and declining speed of corticosteroids measuring
various clinical data is now under investigation in our laboratory.
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